Ph3 of AZD5335 vs. Mirvetuximab Soravtansine in High-Grade PROC (TREVI) (GOG-3127)
Phase III Clinical Trial
Protocol Code: D8991C00001 IND number: 174954Protocol Title: A Randomised Open label Phase III Study of AZD5335 Versus Mirvetuximab Soravtansine in FRα high and AZD5335 Versus Investigator�s Choice Chemotherapy in FRα low Expressing High grade Platinum resistant Epithelial Ovarian Cancer Patients (TREVI-OC-01).